Cytokinetics Inc (CYTK):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cytokinetics Inc (CYTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10087
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases associated with reduced muscle performance. The company’s pipeline encompasses omecamtiv mecarbil, a novel cardiac myosin activator in Phase 3 for heart failure; and reldesemtiv, a next-generation fast skeletal muscle troponin activator in Phase 2 for the treatment of spinal muscular atrophy; chronic obstructive pulmonary disease; and in Phase 1b for frailty. It is also investigating reldesemtiv for amyotrophic lateral sclerosis. It has licensing agreements with Amgen and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

Cytokinetics Inc (CYTK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11
Astellas Pharma Expands Licensing Agreement with Cytokinetics 13
Equity Offering 15
Cytokinetics Plans to Raise Funds through Public Offering of Securities 15
Cytokinetics Prices Public Offering of Shares for USD75 Million 16
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17
Cytokinetics Raises USD10 Million in Private Placement of Shares 18
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 19
Cytokinetics Completes Public Offering Of Shares For US$5 Million 21
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 22
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 24
Cytokinetics Inc – Key Competitors 26
Cytokinetics Inc – Key Employees 27
Cytokinetics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2018: Cytokinetics reports third quarter 2018 financial results 29
Jul 26, 2018: Cytokinetics Reports Second Quarter 2018 Financial Results 31
Apr 26, 2018: Cytokinetics Reports First Quarter 2018 Financial Results 34
Feb 15, 2018: Cytokinetics Reports Fourth Quarter 2017 Financial Results 36
Oct 26, 2017: Cytokinetics Reports Third Quarter 2017 Financial Results 38
Aug 02, 2017: Cytokinetics Reports Second Quarter 2017 Financial Results 40
Apr 27, 2017: Cytokinetics Reports First Quarter 2017 Financial Results 42
Feb 16, 2017: Cytokinetics Reports Fourth Quarter 2016 Financial Results 44
Corporate Communications 47
Feb 12, 2018: Cytokinetics Appoints Robert Califf, M.D., to Board of Directors 47
Product News 48
Nov 30, 2017: New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS 48
Product Approvals 49
May 15, 2017: Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy 49
Clinical Trials 50
Apr 24, 2018: Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference 50
Feb 21, 2018: Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018 51
Jan 03, 2018: Cytokinetics Provides on CK-2127107 52
Dec 11, 2017: Cytokinetics Publishes Clinical Trial Data for CK-2127107 53
Nov 30, 2017: New Publication Summarizes Phase 1 Studies Of CK-2127107 Showing Tolerability And Amplification Of Skeletal Muscle Response To Nerve Activation 54
Jul 27, 2017: Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis 56
Jul 05, 2017: Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA 57
Mar 29, 2017: Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy 59
Mar 22, 2017: Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Cytokinetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11
Astellas Pharma Expands Licensing Agreement with Cytokinetics 13
Cytokinetics Plans to Raise Funds through Public Offering of Securities 15
Cytokinetics Prices Public Offering of Shares for USD75 Million 16
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17
Cytokinetics Raises USD10 Million in Private Placement of Shares 18
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 19
Cytokinetics Completes Public Offering Of Shares For US$5 Million 21
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 22
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 24
Cytokinetics Inc, Key Competitors 26
Cytokinetics Inc, Key Employees 27

List of Figures
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Cytokinetics Inc (CYTK):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sapience Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Sapience Therapeutics Inc (Sapience) is a preclinical-stage biotechnology company that focuses on developing novel therapeutics for major unmet medical needs with special emphasis on high mortality cancers. The company offers peptides that act at the level of transcriptional regulation of on …
  • Grupo Aeroportuario del Sureste SAB de CV:戦略・SWOT・企業財務分析
    Grupo Aeroportuario del Sureste SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Aeroportuario del Sureste SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Business Development Bank of Canada:企業のM&A・事業提携・投資動向
    Business Development Bank of Canada - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Business Development Bank of Canada Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on …
  • Intarcia Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Intarcia Therapeutics Inc (Intarcia), formerly BioMedicines Inc is a biopharmaceutical company that discovers, develops and commercializes drug therapies. The company’s product candidates include ITCA 650, used for the treatment of type II diabetes and obesity. It offers technology platform …
  • Linklaters Llp:企業の戦略・SWOT・財務分析
    Linklaters Llp - Strategy, SWOT and Corporate Finance Report Summary Linklaters Llp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Rosenergoatom Concern JSC:企業の戦略的SWOT分析
    Rosenergoatom Concern JSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Brooks MacDonald Group PLC (BRK)
    Brooks MacDonald Group PLC (BRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Northwest Pipe Co (NWPX):企業の財務・戦略的SWOT分析
    Northwest Pipe Co (NWPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tong Ren Tang Technologies Co Ltd (1666):企業の財務・戦略的SWOT分析
    Summary Tong Ren Tang Technologies Co Ltd (TRTT), a subsidiary of Beijing Tong Ren Tang Co Ltd is a pharmaceutical company that manufactures and supplies Chinese medicines. The company’s products comprise Chinese medicine, healthy food and maier hai cosmetics. It offers products in the forms of pill …
  • K-Electric Ltd (KEL):企業の財務・戦略的SWOT分析
    K-Electric Ltd (KEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Helmerich & Payne Inc (HP):企業の財務・戦略的SWOT分析
    Helmerich & Payne Inc (HP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • HollyFrontier Corp (HFC):石油・ガス:M&Aディール及び事業提携情報
    Summary HollyFrontier Corp (HollyFrontier) is an independent energy company. It carries out crude oil refining and wholesale marketing of refined petroleum products. The company produces and markets high-value light products such as gasoline, diesel, jet fuel, specialty lubricant products, heavy pro …
  • Penn National Gaming Inc:企業のM&A・事業提携・投資動向
    Penn National Gaming Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Penn National Gaming Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • QuadGraphics, Inc. (QUAD):企業の財務・戦略的SWOT分析
    QuadGraphics, Inc. (QUAD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • CITIC Resources Holdings Limited:企業の戦略・SWOT・財務情報
    CITIC Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Resources Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • ACWA Power International:電力:M&Aディール及び事業提携情報
    Summary ACWA Power International (ACWA Power), a subsidiary of ACWA Holding is a power generation company that develops and operates power generation and desalinated water production plants. The company holds a generation portfolio of power and desalinated water. Its projects comprise in selecting i …
  • Pengrowth Energy Corp (PGF):石油・ガス:M&Aディール及び事業提携情報
    Summary Pengrowth Energy Corp (Pengrowth) is an oil and gas company that explores, acquires, develops and produces oil and natural gas reserves. The company's services include development of large accumulations of oil, bitumen and natural gas. Its projects include Lindbergh thermal project, conventi …
  • Energate Inc:企業の戦略的SWOT分析
    Energate Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • RBC Wealth Management:企業の戦略・SWOT・財務情報
    RBC Wealth Management - Strategy, SWOT and Corporate Finance Report Summary RBC Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • CAS Medical Systems Inc (CASM):企業の財務・戦略的SWOT分析
    Summary CAS Medical Systems Inc (CASMED) is a medical device company that designs, manufactures and markets technologies and monitors. The company offers technologies and monitors that deliver patient data. Its products comprise FORE-SIGHT absolute tissue oximeter, blood pressure measurement technol …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆